← boardnext 2026-12next 2028-03
AXSM
Axsome Therapeutics, Inc.distress 0/10 · well-funded / low risk$238.940%today-6% from 52w high
Neurology 1
Lead: cataplexy in narcolepsy · target DAT/NET
Revenue
$191M
Liquidity
$305M
Runway
4.3 yrs
Shares 1y
+3%
Price & events
+27.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
+0.8%
1W
-1.3%
1M
+30.8%
3M
+28.5%
6M
+124.7%
1Y
+178.9%
2Y
+345.1%
5Y
+193.4%
All
Overview
- Market Cap
- $12.30B
- Enterprise Value
- $12.11B
- Volume
- 40.23K
- 52 Week Range
- $100 – $255
- Total Shares
- 51.46M
- Float Shares
- 43.56M
- Short %
- 8.02%
- % Held by Insiders
- 15.35%
- % Held by Institutions
- 75.72%
- RVOL
- 0.04x
- Beta
- 0.60
Pipeline stages · 3 programs
Solriamfetol 150 MG
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AXS-14 (esreboxetine)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AXS-05 (dextromethorphan-bupropion)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 8 trials · 5 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 3 | Solriamfetol 150 mg, Solriamfetol 300 mg | Excessive Sleepiness, Shift-work Disorder | — | recruiting |
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 3 | Solriamfetol 75mg, 150 mg, or 300 mg | Binge-Eating Disorder | — | enrolling by invitation |
| 2028-03 Estimated 50% readout ~2028-05-15 | Phase 3 | AXS-14 (Esreboxetine) | Fibromyalgia | — | recruiting |
| 2028-05 Estimated 50% readout ~2028-07-15 | Phase 3 | AXS-14 (esreboxetine) | Fibromyalgia | — | enrolling by invitation |
| 2028-12 Estimated 50% readout ~2029-02-14 | Phase 3 | Solriamfetol 150 MG | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | — | recruiting |
Show all 8 trials · 3 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-12 | Phase 3 | Solriamfetol 150 mg, Solriamfetol 300 mg | Binge-Eating Disorder | 450 | recruiting |
| 2025-02-17 | Phase 3 | AXS-05 (dextromethorphan-bupropion) | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor | 139 | terminated |
| 2025-02-07 | Phase 3 | Solriamfetol 150 mg, Solriamfetol 300 mg | ADHD | 516 | completed |
Catalyst news & presentations · 21
- May 1, 2027PDUFAPDUFAAXS-12 · PDUFA target action date for AXS-12 NDASEC 8-K
- 2026-08-10Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-03partnershipSUNOSI · Settlement agreement with five companies to resolve patent litigation, granting rights to sell generic SUNOSI starting 2040SEC 8-K
- Friday, May 1, at 8:00 AM Eastern Timeconferencedata presentationsecondaryAUVELITY · Company-hosted webcast to discuss FDA approval.SEC 8-K
- 2026-04-01partnershipbalipodect · Axsome acquires exclusive global rights to balipodect from Takeda for schizophrenia and Tourette syndrome.SEC 8-K
- 2026-02-17partnershipSUNOSI (solriamfetol) · Settled patent litigation with Alkem, granting generic licensing rights starting in 2040 subject to regulatory review.SEC 8-K
- January 2026regulatory submissionFiled (NDA/BLA)AXS-12 · NDA submission for AXS-12 for treatment of cataplexy in narcolepsySEC 8-K
- 2025-12-31fda agreementAXS-12 · FDA pre-NDA meeting minutes received supporting NDA submission for AXS-12SEC 8-K
- fourth quarter of 2025trial initiationsecondaryAXS-14 · Axsome to initiate additional controlled trial using fixed-dose, 12-week endpoint as per FDA feedbackSEC 8-K
- fourth quarter 2025regulatory submissionFiled (NDA/BLA)AXS-12 · NDA submission for AXS-12 in narcolepsy with cataplexySEC 8-K
- fourth quarter of 2025trial initiationsecondaryPhase 3solriamfetol · Initiate Phase 3 trial in MDD with EDSSEC 8-K
- third quarter of 2025regulatory submissionFiled (NDA/BLA)AXS-05 · sNDA submission for AXS-05 in Alzheimer's disease agitationSEC 8-K
- 2025-06-09refuse to fileAXS-14 · FDA issued RTF letter for NDA for AXS-14 for fibromyalgia, citing inadequate second trialSEC 8-K
- 2025-05-27partnershipSUNOSI · Axsome grants Hetero a license to sell generic SUNOSI starting September 1, 2040 (with pediatric exclusivity) or March 1, 2040 (without), subject to FDA approval.SEC 8-K
- 2025-05-08partnershipAxsome enters $570M term loan and revolving credit facility with Blackstone.SEC 8-K
- 1Q 2025readoutPhase 3solriamfetol · Topline results of PARADIGM trialSEC 8-K
- January 31, 2025PDUFAPDUFAAXS-07 · PDUFA action goal date for NDA resubmissionSEC 8-K
- 4Q 2024readoutPhase 3AXS-12 · Topline results of ENCORE trialSEC 8-K
- November 2024regulatory submissionFiled (NDA/BLA)AXS-14 · NDA submission anticipatedSEC 8-K
- 2024-09-04fda agreementAXS-07 · FDA acknowledged resubmission of NDA for AXS-07 as Class 2SEC 8-K
- 2024-08-21withdrawalSunosi (solriamfetol) · Sandoz withdrew its ANDA for a generic equivalent of Sunosi, and patent litigation was dismissed without prejudice.SEC 8-K
Approved drugs (2)
- SYMBRAVOMELOXICAM2025 · Prescription
- AUVELITYBUPROPION HYDROCHLORIDE2022 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $280 (+17% upside) · 20 analysts
- 2026-07-21BMO CapitalOutperform
- 2026-07-15HC Wainwright & Co.Buy
- 2026-07-08HC Wainwright & Co.Buy
- 2026-07-07RBC CapitalOutperform
- 2026-06-17TD CowenBuy
- 2026-05-05Morgan StanleyEqual-Weight
Competitors — DAT/NET
- none identified
Recent news
- 2026-07-2368,453 Shares in Axsome Therapeutics, Inc. $AXSM Acquired by Hsbc Holdings PLC - MarketBeat
- 2026-07-22Axsome Therapeutics (NASDAQ:AXSM) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
- 2026-07-22Axsome Therapeutics (NASDAQ:AXSM) Upgraded to "Strong-Buy" at BMO Capital Markets - MarketBeat
- 2026-07-22AXSM Initiated Coverage by BMO Capital -- Outperform Rating Assi - GuruFocus
- 2026-07-22AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism? - Stocktwits
- 2026-07-21Axsome Therapeutics Inc. (AXSM) Q3 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-21Axsome Therapeutics Inc. (AXSM) Q3 2025 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-21BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.